Science

Kristina Lindemann: Norwegian RWD of outcome in patients with advanced and recurrent endometrial cancer

Kristina Lindemann/healthtalk.no

Feb 2, 2025, 18:18

Kristina Lindemann: Norwegian RWD of outcome in patients with advanced and recurrent endometrial cancer

Kristina Lindemann, Head of the Gynecological Oncology Center at Oslo University Hospital, shared an article on LinkedIn:

“We just published real-world data of outcome in patients with advanced and recurrrent endometrial cancer. Molecular classification is crucial for prognostication, also in patients with advanced disease!

Implementation is important for access to immunotherapy, screening for Lynch syndrome as well as potential de-escalation in patients with POLE mutated tumors in the RAINBO program.”

Real-world outcomes in molecular subgroups for patients with advanced or recurrent endometrial cancer treated with platinum-based chemotherapy.

Authors: Kristina Lindemann, et al.

cancer chemotherapy Endometrial cancer fight against cancer Global fight against cancer Kristina Lindemann OncoDaily Oncology Oslo University Hospital RAINBO program

Top 10 Oncogrants of the Week: Advancing Breakthroughs in Cancer Care

Solange Peters Honored with the IASLC Paul A. Bunn, Jr. Scientific Award 2025

World Radiotherapy Awareness Day, September 7: Recognizing the Hidden Hero of Cancer Care

16 Posts Not to Miss From WCLC 2025 Part 1

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham